These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 20450175)

  • 21. Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors.
    Jahnke W; Blommers MJ; Fernández C; Zwingelstein C; Amstutz R
    Chembiochem; 2005 Sep; 6(9):1607-10. PubMed ID: 16028302
    [No Abstract]   [Full Text] [Related]  

  • 22. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
    Simard JR; Rauh D
    Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain.
    Fujita A; Shishido T; Yuan Y; Inamoto E; Narumiya S; Watanabe N
    Mol Pharmacol; 2009 Jan; 75(1):75-84. PubMed ID: 18835981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virtual screening of Abl inhibitors from large compound libraries by support vector machines.
    Liu XH; Ma XH; Tan CY; Jiang YY; Go ML; Low BC; Chen YZ
    J Chem Inf Model; 2009 Sep; 49(9):2101-10. PubMed ID: 19689138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
    ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors.
    Falchi F; Manetti F; Carraro F; Naldini A; Maga G; Crespan E; Schenone S; Bruno O; Brullo C; Botta M
    ChemMedChem; 2009 Jun; 4(6):976-87. PubMed ID: 19326384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
    Brasher BB; Roumiantsev S; Van Etten RA
    Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
    Adrián FJ; Ding Q; Sim T; Velentza A; Sloan C; Liu Y; Zhang G; Hur W; Ding S; Manley P; Mestan J; Fabbro D; Gray NS
    Nat Chem Biol; 2006 Feb; 2(2):95-102. PubMed ID: 16415863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A general strategy for creating "inactive-conformation" abl inhibitors.
    Okram B; Nagle A; Adrián FJ; Lee C; Ren P; Wang X; Sim T; Xie Y; Wang X; Xia G; Spraggon G; Warmuth M; Liu Y; Gray NS
    Chem Biol; 2006 Jul; 13(7):779-86. PubMed ID: 16873026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase.
    Dorey K; Engen JR; Kretzschmar J; Wilm M; Neubauer G; Schindler T; Superti-Furga G
    Oncogene; 2001 Dec; 20(56):8075-84. PubMed ID: 11781820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies.
    Gambacorti-Passerini C; Gasser M; Ahmed S; Assouline S; Scapozza L
    Leukemia; 2005 Jul; 19(7):1267-9. PubMed ID: 15858616
    [No Abstract]   [Full Text] [Related]  

  • 33. Allosteric modulation of myristate and Mn(III)heme binding to human serum albumin. Optical and NMR spectroscopy characterization.
    Fanali G; Fesce R; Agrati C; Ascenzi P; Fasano M
    FEBS J; 2005 Sep; 272(18):4672-83. PubMed ID: 16156788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
    Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
    Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
    Wang Y; Shakespeare WC; Huang WS; Sundaramoorthi R; Lentini S; Das S; Liu S; Banda G; Wen D; Zhu X; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Dalgarno D; Clackson T; Sawyer TK
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4907-12. PubMed ID: 18691885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
    Zhou T; Commodore L; Huang WS; Wang Y; Sawyer TK; Shakespeare WC; Clackson T; Zhu X; Dalgarno DC
    Chem Biol Drug Des; 2010 Jan; 75(1):18-28. PubMed ID: 19895503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening.
    Cheeseright TJ; Holm M; Lehmann F; Luik S; Göttert M; Melville JL; Laufer S
    J Med Chem; 2009 Jul; 52(14):4200-9. PubMed ID: 19489590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.
    Yang LJ; Zou J; Xie HZ; Li LL; Wei YQ; Yang SY
    PLoS One; 2009 Dec; 4(12):e8470. PubMed ID: 20041122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug discovery and the human kinome: recent trends.
    Eglen R; Reisine T
    Pharmacol Ther; 2011 May; 130(2):144-56. PubMed ID: 21256157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-(thiazol-2-yl)-2-thiophene carboxamide derivatives as Abl inhibitors identified by a pharmacophore-based database screening of commercially available compounds.
    Manetti F; Falchi F; Crespan E; Schenone S; Maga G; Botta M
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4328-31. PubMed ID: 18621522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.